NTLA · Intellia Therapeutics, Inc. · Webcasts, Transcripts & Audio
$12.26
+0.14 (+1.16%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.65B
Shares
140.13M
Volume · Oct 2
4.5M
Avg daily vol (3M)
3.99M
Intellia Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Intellia Therapeutics, Inc. (NTLA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲84.1%
$13.27M
−$113.23M
'22 Q3
22-11-03
▲5.6%
$13.57M
−$113.41M
'22 Q4
23-01-05
▲12%
$12.61M
−$103.13M
'23 Q1
23-05-04
▼3.1%
$13.59M
−$123.68M
'23 Q2
23-08-03
▼9.6%
$11.99M
−$122.22M
'23 Q3
23-11-09
▼114.1%
$
−$132.16M
'23 Q4
24-02-22
▲129.5%
$28.93M
−$107.44M
'24 Q1
24-05-09
▼48.8%
$6.96M
−$146.97M
'24 Q2
24-08-08
▼24%
$9.11M
−$135.71M
'24 Q3
24-11-07
·
$12.87M
−$128.90M
'24 Q4
25-01-10
▼42.5%
$16.63M
−$114.33M
'25 Q1
25-05-08
▲104.8%
$14.24M
−$101.25M
'25 Q2
25-08-07
▲51.3%
$13.78M
−$101.32M
'25 Q3
25-11-06
▲78.8%
$23.02M
−$95.79M
'25 Q4
26-02-26
▼9.5%
$15.05M
−$96.23M
'26 Q1
26-04-27
LATEST
▼46.2%
$7.66M
−$106.63M
'26 Q2
26-08-06
Conference
Investor event
2026-09-14
Intellia Therapeutics, Inc. (NTLA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Confident tone
NEXE in ATTR cardiomyopathy and polyneuropathy
Lombosi HALO Phase 3 results in HAE
HLA genotyping safety finding
Revenue
$7.66M
▼ 46.2% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-27
Intellia Therapeutics, Inc. (NTLA) Q1 2026 Earnings Call
Revenue
$15.05M
▼ 9.5% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Positive tone
HAE market research and demand
nex-z and MAGNITUDE clinical hold
lonvo-z / HAELO Phase 3 readout
Revenue
$23.02M*
▲ 78.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Cautious tone
nex-z safety event and clinical hold
MAGNITUDE and MAGNITUDE-2 trials
lonvo-z (HAE) program progress
Revenue
$13.78M
▲ 51.3% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Confident tone
ATTR cardiomyopathy / nex-z (MAGNITUDE)
Enrollment acceleration & guidance update
Commercial / launch readiness
Revenue
$14.24M
▲ 104.8% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript
Confident tone
NTLA-2002 for HAE
Enrollment & Trial Timeline
Nexiguran Ziclumeran (Nex-Z) for ATTR
Revenue
$16.63M
▼ 42.5% YoY Diluted EPS
$-1.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript
Confident tone
Nex-z for ATTR amyloidosis with cardiomyopathy
Phase III enrollment progress
NTLA-2002 for hereditary angioedema (HAE)
Revenue
$12.87M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript
Confident tone
NTLA-2002 for Hereditary Angioedema (HAE)
NEX-Z (NTLA-2001) for ATTR Amyloidosis
Phase III trial execution and enrollment momentum
Revenue
$9.11M
▼ 24% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript
Confident tone
NTLA-2002 (HAE) pivotal program
NTLA-2001/NEX-Z (ATTR amyloidosis)
Commercialization preparation
Revenue
$6.96M
▼ 48.8% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript
Confident tone
ATTR program (NTLA-2001) and MAGNITUDE Phase III
Regulatory milestones and BLA
Pipeline expansion into new tissues
Revenue
$28.93M
▲ 129.5% YoY Diluted EPS
$-1.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Intellia Therapeutics, Inc. (NTLA) Q4 2023 Earnings Call Transcript
Confident tone
NTLA-2001 / ATTR amyloidosis Phase 3 MAGNITUDE
NTLA-2002 / HAE program
Gene insertion platform
Revenue
$*
▼ 114.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript
Revenue
$11.99M
▼ 9.6% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Intellia Therapeutics, Inc. (NTLA) Q2 2023 Earnings Call Transcript
Revenue
$13.59M
▼ 3.1% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript
Revenue
$12.61M
▲ 12% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Intellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call Transcript
Revenue
$13.57M*
▲ 5.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Intellia Therapeutics, Inc. (NTLA) Q3 2022 Earnings Call Transcript
Revenue
$13.27M
▲ 84.1% YoY Diluted EPS
$-1.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Intellia Therapeutics, Inc. (NTLA) Q2 2022 Earnings Call Transcript
Revenue
$14.03M
▲ 114.2% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Intellia Therapeutics, Inc. (NTLA) Q1 2022 Earnings Call Transcript
Revenue
$11.25M
▲ 74.6% YoY Diluted EPS
$-1.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-06
Intellia Therapeutics, Inc. (NTLA) Q4 2021 Earnings Call Transcript
Revenue
$12.85M*
▲ 94.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Intellia Therapeutics, Inc. (NTLA) Q3 2021 Earnings Call Transcript
Revenue
$7.20M
▼ 67.6% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Intellia Therapeutics, Inc. (NTLA) Q2 2021 Earnings Call Transcript
Revenue
$6.55M
▼ 59.7% YoY Diluted EPS
$-1.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
Revenue
$6.45M
▼ 50.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript
Revenue
$6.59M
▼ 39.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Intellia Therapeutics, Inc. (NTLA) Q3 2020 Earnings Call Transcript
Revenue
$22.22M
▲ 109.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Intellia Therapeutics, Inc. (NTLA) Q2 2020 Earnings Call Transcript
Revenue
$16.26M
▲ 46.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Intellia Therapeutics, Inc. (NTLA) Q1 2020 Earnings Call Transcript
Revenue
$12.92M
▲ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call
Revenue
$10.94M
▲ 38.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1652130
CUSIP
45826J105
13F (30d)
10 filings
6 filers
Visit website
Investor relations